期刊
BRITISH JOURNAL OF PHARMACOLOGY
卷 172, 期 4, 页码 957-974出版社
WILEY
DOI: 10.1111/bph.12979
关键词
-
资金
- British Heart Foundation [FS/11/67/28954] Funding Source: researchfish
- Cancer Research UK [19278] Funding Source: researchfish
- Medical Research Council [MR/L006758/1] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0512-10064] Funding Source: researchfish
- MRC [MR/L006758/1] Funding Source: UKRI
- British Heart Foundation [FS/11/67/28954] Funding Source: Medline
- Medical Research Council [MR/L006758/1] Funding Source: Medline
- NHLBI NIH HHS [R01 HL119234] Funding Source: Medline
The incidence of drug-induced structural cardiotoxicity, which may lead to heart failure, has been recognized in association with the use of anthracycline anti-cancer drugs for many years, but has also been shown to occur following treatment with the new generation of targeted anti-cancer agents that inhibit one or more receptor or non-receptor tyrosine kinases, serine/threonine kinases as well as several classes of non-oncology agents. A workshop organized by the Medical Research Council Centre for Drug Safety Science (University of Liverpool) on 5 September2013 and attended by industry, academia and regulatory representatives, was designed to gain a better understanding of the gaps in the field of structural cardiotoxicity that can be addressed through collaborative efforts. Specific recommendations from the workshop for future collaborative activities included: greater efforts to identify predictive (i) preclinical; and (ii) clinical biomarkers of early cardiovascular injury; (iii) improved understanding of comparative physiology/pathophysiology and the clinical predictivity of current preclinical in vivo models; (iv) the identification and use of a set of cardiotoxic reference compounds for comparative profiling in improved animal and human cellular models; (v) more sharing of data (through publication/consortia arrangements) on target-related toxicities; (vi) strategies to develop cardio-protective agents; and (vii) closer interactions between preclinical scientists and clinicians to help ensure best translational efforts.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据